SLC5A2 and type 2 diabetes mellitus: In clinical trials of SGLT2 inhibitors in type 2 diabetes, discontinuation rates among those receiving active treatment have been less variable, ranging from 21% during a median follow-up time of 50 months in the DECLARE-TIMI 58 trial of dapagliflozin to 29% during a mean follow-up time of 43 months in the CANVAS trial of canagliflozin [14–18].